- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
- Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
- Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
- Akari Therapeutics to Present at Emerging Growth Conference
- Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
- Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
- Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
- Akari Therapeutics, Plc Announces ADS Ratio Change
More ▼
Key statistics
On Friday, Akari Therapeutics PLC (AKTX:NAQ) closed at 1.19, 9.98% above its 52-week low of 1.08, set on Apr 17, 2024.
52-week range
Open | 1.19 |
---|---|
High | 1.20 |
Low | 1.17 |
Bid | 1.15 |
Offer | 1.48 |
Previous close | 1.19 |
Average volume | 8.43k |
---|---|
Shares outstanding | 396.18k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 9.39m USD |
EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:59 BST.
More ▼